NeoGenomics, Inc. (NEO) — Fair Value Analysis

Base-case fair value (P50): $13.50 · Current price: $8.73 · Verdict: Undervalued

The Verdict on NEO

NEOGENOMICS INC (NEO) appears deeply undervalued according to sophisticated Monte Carlo simulations, with its current market price substantially below the median fair value. Our quantitative analysis identifies NEO's current trading price at $8.73, while the probabilistic models place its median fair value (P50) at a robust $13.50. This significant disparity suggests a potential upside of +54.6% against the current market quote. The Monte Carlo approach, by simulating thousands of forward scenarios, points to a strong disconnect between market perception and intrinsic valuation, categorizing NEO as a compelling opportunity based purely on quantitative fair value modeling.

How NEO stacks up against peers

Despite the compelling valuation, NEO’s operational and financial health is currently rated as an average quality tier when benchmarked against its sector peers. This average quality tier indicates that while NEOGENOMICS INC isn't an industry laggard, it also doesn't possess standout operational advantages that would typically command a premium. However, the substantial gap between the current price of $8.73 and the median fair value of $13.50 implies the market might be overly pessimistic regarding the company's prospects, or not fully appreciating its longer-term potential. This +54.6% implied upside, despite an average quality tier, suggests market sentiment or transient factors are heavily influencing the stock's current valuation more than its underlying operational performance relative to its industry.

What this means for investors

For investors, the deeply undervalued verdict for NEO, underscored by a median fair value (P50) of $13.50 against a current price of $8.73, presents a clear quantitative signal. The substantial +54.6% potential upside indicated by our Monte Carlo simulations suggests NEOGENOMICS INC could offer considerable alpha if the market begins to re-price the stock closer to its intrinsic value. Even with an average quality tier, this significant valuation gap suggests the stock is currently priced for a much more challenging future scenario than what the probabilistic models project as the most probable outcome. Investors seeking a comprehensive understanding of the full bear and bull case distributions for NEOGENOMICS INC should sign up for a free FairCurve account to track its fair value as new fundamentals are released.